Evidence map›Paper›PMID 39273186›Full record

ReviewInternational journal of molecular sciences2024

The Role of Furin and Its Therapeutic Potential in Cardiovascular Disease Risk.

Hannah Fry, Mohsen Mazidi, Christiana Kartsonaki, Robert Clarke, Robin G Walters, Zhengming Chen, Iona Y Millwood

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hannah FryNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.ORCID 0009-0006-1584-2042
Mohsen MazidiNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Christiana KartsonakiNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.ORCID 0000-0002-3981-3418
Robert ClarkeNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Robin G WaltersNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.ORCID 0000-0002-9179-0321
Zhengming ChenNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Iona Y MillwoodNuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.

Funding

Medical Research Council 212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/ZWellcome Trust 212946/Z/18/ZWellcome Trust 212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z
6 · The paper itself

Abstract

Furin is an important proteolytic enzyme, converting several proteins from inactive precursors to their active forms. Recently, proteo-genomic analyses in European and East Asian populations suggested a causal association of furin with ischaemic heart disease, and there is growing interest in its role in cardiovascular disease (CVD) aetiology. In this narrative review, we present a critical appraisal of evidence from population studies to assess furin's role in CVD risk and potential as a drug target for CVD. Whilst most observational studies report positive associations between furin expression and CVD risk, some studies report opposing effects, which may reflect the complex biological roles of furin and its substrates. Genetic variation in

Indexed as

Cardiovascular DiseasesFurinAnimalsHumansRisk FactorsFurinFURIN protein, humancardiovascular diseasedrug targetsfuringeneticsproteomics

Identifiers

PMID39273186
PMCPMC11394739

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.